TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Sanofi And Regeneron
Press Release:  ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

Sanofi and Regeneron's Dupixent demonstrated significant improvements in treating allergic fungal rhinosinusitis (AFRS) in a phase 3 study, with the FDA accepting the supplemental biologics license application for priority review.

Insights
SNY   positive

Positive clinical trial results, FDA priority review acceptance, potential new treatment indication expanding Dupixent's market